Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Authors
Batchelor, TMulholland, P
Neyns, B
Nabors, L
Campone, M
Wick, A
Mason, W
Mikkelsen, T
Phuphanich, S
Ashby, L
Degroot, J
Gattamaneni, Rao
Cher, L
Rosenthal, M
Payer, F
Jürgensmeier, J
Jain, R
Sorensen, A
Xu, J
Liu, Q
van den Bent, M
Affiliation
Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.Issue Date
2013-08-12
Metadata
Show full item recordAbstract
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.Citation
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. 2013: J Clin OncolJournal
Journal of Clinical OncologyDOI
10.1200/JCO.2012.47.2464PubMed ID
23940216Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2012.47.2464
Scopus Count
Collections
Related articles
- A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
- Authors: Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF
- Issue date: 2016 Sep
- Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
- Authors: Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK
- Issue date: 2010 Jun 10
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
- Authors: Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ
- Issue date: 2014 Aug
- Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
- Authors: Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ
- Issue date: 2015 Jul 14
- Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
- Authors: Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Clifton-Hadley L, Wanek K, Krell D, Jeffries S, Khan I, Smith P, Mulholland P
- Issue date: 2016